FDA revisits DTC advertising

Young, Donna
December 2005
American Journal of Health-System Pharmacy;12/15/2005, Vol. 62 Issue 24, p2580
Academic Journal
The article reports on the re-evaluation conducted by the Food & Drug Administration (FDA) on the implementation of direct-to-consumer prescription drug advertising in the U.S. The agency is considering whether to impose stricter requirements for medication commercials aimed at consumers. A brief summary of the previous FDA evaluation is discussed in this article.


Related Articles

  • DTC device ads have merit. Hempstead, Susan // Medical Marketing & Media;Jan2006, Vol. 41 Issue 1, p93 

    The article reports that the U.S. Food and Drug Administration (FDA) has sponsored a series of public meetings to solicit information and views about direct-to-consumer (DTC) promotion of prescription drug products through print, broadcast or other types of media. DTC media-product...

  • NOTHING BUT BLUE SKIES? Thomaselli, Rich // Advertising Age;10/2/2006, Vol. 77 Issue 40, p3 

    The article focuses on the status of direct-to-consumer (DTC) television advertising from drug companies in the U.S. Since the Food and Drug Administration's decision to relax the guidelines regarding DTC advertisements, the category has emerged from a dawdling $12 million business to a $4.1...

  • Turf War Escalates Over Big Pharma Marketing. Edwards, Jim // Brandweek;11/7/2005, Vol. 46 Issue 40, p6 

    This article focuses on the efforts of the U.S. Food and Drug Administration to review policies on direct-to-consumer (DTC) drug advertising as of November 2005. The policies were brought about by the pleas of parties wanting to ban DTC advertising. While no marketer proposed a total advertising...

  • Presenting Risk in Drug Advertising. Heisey, Colleen; Chernove, Arianna // Contract Pharma;Sep2010, Vol. 12 Issue 7, p18 

    The article focuses on the publication of a proposed rule by the U.S. Food and Drug Administration (FDA) that is aimed for the amendment of radio and television direct-to-consumer (DTC) advertising regulations for prescription drugs. The amendment seeks to include standards by which FDA will...

  • Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations: GAO-03-177.  // GAO Reports;10/28/2002, p1 

    Prescription drug spending increased at an annual rate of 18 percent from 1997 through 2001 and is the fastest growing component of health care spending in the United States. Among the many reasons cited for this increase are growth in the number of patients diagnosed with conditions that can be...

  • Legislators may move on DTC drug advertising. Goetzl, David; Teinowitz, Ira // Advertising Age;4/2/2001, Vol. 72 Issue 14, p3 

    Discusses direct-to-consumer (DTC) drug advertising in the United States. There is a possibility of legislation to set advertising standards. Factors that influence the high cost of prescription drugs are discussed. The loosening of regulations by the U.S. Food and Drug Administration have...

  • FDA would up PDUFA for DTC reviews. Arnold, Matthew // Medical Marketing & Media;Feb2007, Vol. 42 Issue 2, p28 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to raise user fee in its review of the direct-to-consumer advertising of prescription drugs. Under the FDA plan, the budget for Prescription Drug User Fee Act (PDUFA) will be increased by $87.4 million annually to...

  • DTC user fee plan canned. M. A. // Medical Marketing & Media;Feb2008, Vol. 43 Issue 2, p28 

    The article reports that the Food and Drug Administration (FDA) has advised that the direct-to-consumer (DTC) television (TV) advertising user program will not commence as required by the FDA Amendments Act of 2007 (FDAAA) in the U.S. The user fee program for advisory review of advertisements...

  • FDA asked to require warnings on DTC ads for implanted devices. Long, Don // Biomedical Business & Technology;Jan2008, Vol. 31 Issue 1, p26 

    The article reports on a petition to require warnings on direct-to-consumer (DTC) advertising for implanted devices filed by the Washington-based Consumers Union (CU) to the U.S. Food and Drug Administration (FDA). The CU calls for the inclusion of warnings about the possibility of dangerous...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics